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A B S T R A C T
Native highlanders (e.g. Sherpa) demonstrate remarkable hypoxic tolerance, possibly secondary to higher levels
of circulating nitric oxide (NO) and increased microcirculatory blood flow. As part of the Xtreme Alps study (a
randomised placebo-controlled trial of dietary nitrate supplementation under field conditions of hypobaric
hypoxia), we investigated whether dietary supplementation with nitrate could improve NO availability and
microvascular blood flow in lowlanders. Plasma measurements of nitrate, nitrite and nitroso species were per-
formed together with measurements of sublingual (sidestream dark-field camera) and forearm blood flow (ve-
nous occlusion plethysmography) in 28 healthy adult volunteers resident at 4559m for 1 week; half receiving a
beetroot-based high-nitrate supplement and half receiving an identically-tasting low nitrate ‘placebo’. Dietary
supplementation increased plasma nitrate concentrations 4-fold compared to the placebo group, both at sea level
(SL; 19.2 vs 76.9 μM) and at day 5 (D5) of high altitude (22.9 vs 84.3 μM, p < 0.001). Dietary nitrate sup-
plementation also significantly increased both plasma nitrite (0.78 vs. 0.86 μM SL, 0.31 vs. 0.41 μM D5,
p= 0.03) and total nitroso product (11.3 vs. 19.7 nM SL, 9.7 vs. 12.3 nM D5, p < 0.001) levels both at sea level
and at 4559m. However, plasma nitrite concentrations were more than 50% lower at 4559m compared to sea
level in both treatment groups. Despite these significant changes, dietary nitrate supplementation had no effect
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on any measured read-outs of sublingual or forearm blood flow, even when environmental hypoxia was ex-
perimentally reversed using supplemental oxygen. In conclusion, dietary nitrate supplementation does not im-
prove microcirculatory function at 4559m.
1. Introduction
Atmospheric pressure, and consequently the partial pressure of
oxygen, both decrease with increasing altitude. This hypobaric hypoxia
can cause many challenges to those visiting or living in highland re-
gions, including serious illnesses which can prove fatal if left untreated
[1,2]. Yet given appropriate time to acclimatise (the process by which
an individual adapts physiologically to environmental changes such as
hypobaric hypoxia), humans have been able to successfully reach ex-
treme altitudes despite remarkably low environmental levels of oxygen
[3]. Intuitively, the factors considered most important to mounting a
successful acclimatisation response are usually those that result in
global circulatory changes and enhance tissue oxygen delivery; e.g.
increased heart rate, cardiac output and erythropoiesis [2]. However,
detailed physiological profiling of a number of world-class high altitude
mountaineers showed remarkably little differences in all reported
measures of global circulatory performance [4]. Similarly, Sherpas,
who are renowned for their exceptional performance at extreme alti-
tudes, display only modest levels of erythropoiesis [5–8]. However,
both elite high altitude mountaineers and Sherpas demonstrate sig-
nificantly higher muscle capillary densities than lowlander controls,
suggesting that excellent altitude performance might, at least in part, be
due to differences in microcirculatory function (such as exercise-in-
duced angiogenesis or simply smaller fiber atrophy) [4,9]. The pro-
portion of capillaries actually supporting red blood cell flux may be
even more important than muscle oxygen diffusing capacity in de-
termining overall microvascular oxygen pressures [10].
The microcirculation refers to the smallest blood vessels in the body,
typically those less than 100 μm in diameter, and microcirculatory
dysfunction is increasingly being implicated in the development of
critical illnesses, sepsis and other shock states [11,12]. Novel non-in-
vasive techniques, such as sidestream dark-field (SDF) imaging, have
only recently allowed direct visualisation of the human microcircula-
tion [13,14]; particularly, the sublingual microcirculation, which is
easily monitored and might offer a convenient proxy for other vascular
beds. For example, the proportion of vessels flowing in the sublingual
bed closely coheres with the latest measurements within skeletal
muscle (approximately 80%) [15]. Recent studies using these techni-
ques suggested that microcirculatory blood flow significantly decreased
in lowlanders at altitude, particularly in small (< 25 μm) diameter
vessels [16,17]. However at 5300m, Sherpas demonstrated sig-
nificantly higher microcirculatory blood flow than resident lowlanders
[18]. Similarly, forearm blood flow (an indirect measure of micro-
circulatory status at the level of resistance arteries) in Sherpas was more
than twice that in lowlanders, and these responses were closely asso-
ciated with significant increases in circulating concentrations of plasma
nitrate and nitrite, indicative of increased nitric oxide (NO) formation
and/or bioavailability [19].
NO is a ubiquitous cellular messenger and effector molecule (be-
longing to a group of small molecules often referred to as ‘gaso-
transmitters’) with potent vasoactive and anti-inflammatory properties
[20–22]. Physiologically, NO is produced from L-arginine by a family of
isoenzymes known as ‘nitric oxide synthases’ (NOS) (usually co-ex-
pressed with arginase enzymes in smooth muscle) in an oxygen-de-
pendent process; an alternative pathway is thought to proceed through
serial reduction of inorganic nitrate (NO3−) to nitrite (NO2−) and then
finally to NO. This latter process is promoted by hypoxic conditions
because oxygen normally inhibits the reduction process [23], which
might explain the significant increases in NO metabolism observed at
altitude [24]. Dietary nitrate may be converted to NO through a similar
mechanism; after being reduced to nitrite by oral commensal bacteria,
it may be further reduced to NO by chemical processes inside the sto-
mach and enzymatic bioactivation in the vasculature and other tissues
[25–27]. Inorganic nitrate supplementation with beetroot juice has al-
ready been shown to improve vascular control and elevate skeletal
muscle oxygen delivery (particularly in fast-twitch II fibres) in ex-
ercising rats [28].
The Xtreme Alps expedition was a double-blinded randomised pla-
cebo-controlled trial to investigate whether dietary nitrate supple-
mentation could improve performance at altitude, and a full study
methodology has been published elsewhere [29]. The first results from
the Xtreme Alps study have demonstrated that this dietary supple-
mentation is safe and successfully increases pulmonary NO availability;
but surprisingly without significantly affecting measures of global cir-
culatory function, such as heart rate or blood pressure [30]. In this
second report, we hypothesised that if dietary nitrate supplementation
could increase circulating NO levels as well as increasing pulmonary
NO availability, then it might perhaps improve microcirculatory func-
tion at altitude.
2. Methods
2.1. Study settings and participants
Ethical approval for the Xtreme Alps study was obtained from
Research Ethics Committees at both University College London, UK and
the University of Turin, Italy, which manages a research laboratory
inside the Capanna Regina Margherita (‘Margherita Hut’) on the
summit of Monte Rosa (altitude 4559m) where the study was per-
formed in August 2010. Complete methods of the Xtreme Alps ex-
pedition and protocols have been described elsewhere [29]. Healthy
volunteers (aged 18 years and above) were recruited primarily from an
electronic mailing list of individuals interested in altitude research and
physiology. Twenty-eight volunteers participated in total (75% male);
with a mean age of 28.9 years (range 21–40), mean weight 73.3 Kg
(± 11.6), mean height 1.76m (±0.08), and mean BMI 23.6 (± 2.69);
3.6% were smokers and 75% had previously ascended above 3000m.
All volunteers gave written informed consent and completed a health
screening process (as detailed in Ref. [29]) before participating; anyone
considered unfit to perform exercise at high altitude (as previously
explained [31]) was excluded.
Baseline measurements were taken in London (altitude 75m, mean
barometric pressure 100.5 kPa, mean laboratory temperature 24.1 °C
and mean oxygen partial pressure 19.7 kPa). Participants were sepa-
rated into 2 trekking groups (Trek 1 and Trek 2) based on their avail-
ability, with Trek 1 starting their ascent seven days before Trek 2. All
trekkers initially flew into Milan (102m) and remained there overnight
before starting to ascend. The following day, participants travelled by
road to Alagna (1205m), ascended to Punta Indren (3250m) using lifts
and then walked to the Gnifetti Hut (3611m). We planned for both
trekking groups to acclimatise at 3611m for 3 nights before continuing
to ascend on foot to the Margherita Hut (4559m). However, incoming
storms forced Trek 1 to ascend to 4559m one day earlier than Trek 2,
i.e. after spending only two nights at 3611m. After reaching the
Margherita Hut, participants remained at 4559m for the duration of the
study (eight nights for Trek 1 & seven for Trek 2, see Fig. 1) before
descending. In the laboratory at 4559m the mean barometric pressure
was 78.1 kPa, mean ambient temperature 22.6 °C and mean partial
pressure of oxygen calculated to be 15.1 kPa.
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2.2. Intervention and randomisation
Participants were allocated at random (in accordance with the
CONSORT 2010 guidelines, http://www.consort-statement.org/) to
receive either an intervention or placebo version of a custom for-
mulated all-natural beetroot/fruit juice drink (produced and provided
by Aurapa GmbH, Bietigheim-Bissingen, Germany) starting 72 h before
and continuing for the duration of each testing period (i.e. both sea
level and altitude). The low nitrate supplement (placebo group) con-
tained only 11.5 μmol/kg per day (split into three equal doses to be
taken at each mealtime) as the majority of the nitrate content of the
beetroot portion had been removed by a microbial denitrification pro-
cess; whilst in the high nitrate supplement (intervention/treatment)
group the total daily nitrate content was approximately
0.10–0.18mmol/kg/day (again split over three doses for consumption
together with meals) [30]. This intervention dose is very similar to
levels demonstrated previously to improve exercise performance at sea
level [32,33]. Participants and investigators both remained blinded to
group allocations for the duration of the study, including the analysis of
the primary data sets. All other meals during the study period were
standardised to minimise extra nitrate intake in both groups, and the
nitrate content of each meal was measured and recorded as has been
reported previously [30].
2.3. Collection of blood samples and measurement of hemoglobin
Fasted venous blood samples (5ml) were taken at sea level and on
the 1st, 3rd and 5th testing mornings (D1, D3 & D5) during the study at
altitude, using EDTA-containing BD Vacutainer™ tubes. Each of these
samples was immediately centrifuged at 800×g for 15min, and 1ml of
plasma and the red blood cell pellet were both aliquoted into individual
cryovials and frozen at −40 °C for transport back to sea level where
they were stored at −80 °C until later analysis.
Blood haemoglobin (Hb) concentrations were quantified in the field
immediately after sampling using a handheld photometric device
(HemoCue® Whole Blood Haemoglobin System, HemoCue AB,
Angelhoim, Sweden). Measurement ‘cuvettes’ for the HemoCue were
always stored within a thermostatically controlled storage unit in ac-
cordance with the manufacturer's recommendations.
2.4. Plasma biomarker analysis
All plasma biomarker concentrations were quantified after reaction
with an excess of N-ethylmaleimide (NEM, in PBS; 10mM final con-
centration) immediately after frozen plasma aliquots were thawed. To
quantify plasma nitrite and nitrate concentrations, NEM-treated sam-
ples were deproteinized with methanol (1:1) and centrifuged at
16,100×g for 10min before undergoing analysis by high-pressure li-
quid chromatography (HPLC) using a dedicated nitrite/nitrate analyzer
(ENO20, Eicom). All sample analysis was performed with repeated
daily calibrations and staggered to ensure processing times were si-
milar, and all reported values were corrected for background levels of
nitrite/nitrate. Total nitroso product concentrations were quantified by
group-specific denitrosation of NEM-treated EDTA plasma samples after
injecting samples incubated with acidic sulfanilamide directly into an
acidic triiodide-containing reaction chamber and measuring the NO
produced (following reduction of protein nitroso-species) by gas phase
chemiluminescence (CLD 77am sp, EcoPhysics) as described previously
[34]. Circulating plasma levels of L-arginine were measured spectro-
photometrically (SpectraMax M5, Molecular Devices, Sunnyvale, CA,
USA) using a commercial assay (L-Arg ELISA, CEB938Ge 96, Cloud-
Clone Corp, Wuhan, China). Plasma arginase activity was also mea-
sured spectrophotometrically (Sigma-Aldrich MAK112, Dorset, UK).
2.5. Sublingual microcirculatory function
The sublingual microcirculation was imaged whilst resting in a su-
pine position by sidestream dark field (SDF) imaging; a non-invasive
hand-held video microscope (MicroVision Medical, Amsterdam,
Netherlands) was placed under participants' tongues with the camera-
tip pointing sublingually. The probe was moved around gently until
clear images of the microcirculation were displayed, then retracted as
much as possible without losing these images to minimise pressure-flow
artefacts. Four repeat 20-s films were recorded from each subject, first
at sea level and then again after residing at 4559m for at least 4 days.
These were assessed later using the Automated Vascular Analysis (AVA)
3.0 microcirculatory analysis software (MicroVision Medical,
Amsterdam, Netherlands) by two trained and experienced investigators
who were both blinded to the subjects’ identity and also to the location
of each recording (either sea level or altitude).
Microcirculatory Flow Index (MFI) scores were calculated by vessel
size in accordance with recognized guidelines [35]. Initially, each video
image was divided into quadrants and all visualized blood vessels were
sized into small (< 25 μm), medium (26–50 μm) or large blood vessels
(51–100 μm) using a calibrated microgrid. An overall MFI score was
calculated for each vessel size using an internationally recognized flow
grading system (0 for no flow, 1 for intermittent flow, 2 for slow flow or
3 for continuous/normal flow), first averaging the 4 quadrant scores in
each individual recording and then averaging the overall scores ob-
tained from each recording, either at sea level or at altitude.
The AVA 3.0 software was also used to calculate the vessel density.
The position of blood vessel walls needs to be deduced in SDF imaging
using changes in contrast between hemoglobin near the very edge of
blood vessels and surrounding tissues. After image stabilization, time
averaging of individual film frames filled interruptions in perceived
vessel walls caused by plasma gaps and white blood cells. This slope of
change in color was then used to define and trace out blood vessel edges
automatically, allowing the software to calculate small vessel density
(SVD;< 25 μm diameter), medium vessel density (MVD;>25 μm
diameter) and total vessel density (TVD; TVD = SVD + MVD), mea-
sured in mm . mm−2.
2.6. Forearm blood flow measurements
All participants underwent a non-invasive assessment of forearm
blood flow in their dominant arm using strain gauge venous occlusion
plethysmography (EC6 with rapid cuff inflator EC20/AG101 and NIVP3
software; D. E. Hokanson, Inc., Bellevue, WA, USA). An appropriately
sized mercury-in-silastic strain gauge was placed just distal to the
Fig. 1. Ascent profile used during the Xtreme Alps expedition as shown pre-
viously in Ref. [30]. Trek 1 and Trek 2 are represented by solid and dotted lines
respectively. Trek 1 ascended from the Gnifetti Hut (3611m) to the Margherita
Hut (4559m) one day earlier than Trek 2 due to inclement weather conditions.
Each arrow represents the administration of 3 doses of either treatment or
placebo supplement (1 dose before every meal each day), starting 3 days prior
to each testing period. SL= sea level testing, D1 – D5= altitude testing days
1–5.
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antecubital fossa, where the forearm circumference was largest, as the
subject sat with their arm resting on styrofoam blocks elevated to the
level of the right atrium. Initially, blood pressure cuffs placed around
the wrist (inflated to 250mmHg) and the upper arm (inflated to
50mmHg) were used to exclude the hand circulation and occlude ve-
nous outflow from the forearm, and blood flow measurements as well as
oxygen saturation levels were recorded at rest. Both cuffs were then
deflated and after resting for 1min, participants completed a standard
forearm exercise protocol (repeated hand-squeezes of a foam ball at a
frequency of 0.5 Hz for 2min). Immediately following this handgrip
exercise, both cuffs were re-inflated and subsequent circumference
changes recorded. With venous outflow occluded, continuous arterial
inflow led to linear increases in forearm circumferences, which are
reported as the percentage changes of the slopes per minute generated.
In accordance with classical venous occlusion plethysmography, five
repeat values were recorded for each measurement. However, as de-
scribed by our group previously [36], although repeated measures
protocols such as this depict reliability and reproducibility of the
technique being employed when recording baseline levels, averaging in
this way actually provides little information about our primary interest,
microcirculatory vessel recruitment and the resultant increases in blood
flow, after an exercise intervention aimed at stimulating metabolic
demand and thus maximising regional blood flow. The reason for this is
that the flow increases observed are transient in most individuals.
Consequently, here we only report and analyse initial slope increases,
which are indicative of the Maximal Flow Response [36].
After taking measurements under ‘normal’ environmental condi-
tions (i.e. 21% oxygen at sea level, and environmental hypobaric hy-
poxia at 4559m altitude), all participants underwent further testing
with these environmental conditions experimentally ‘reversed’.
Specifically, after normal sea level measurements were taken, all par-
ticipants were subjected to breathing a hypoxic gas mixture (12%
oxygen) for 45min before repeating the measurement protocol; and
similarly, measurements were repeated at 4559m after participants
breathed 35% oxygen for 45min. All responses were normalised to total
forearm volume, determined individually by volume displacement.
2.7. Analysis plan
Statistical analysis was performed using linear mixed modelling in
STATA 11 (http://www.stata.com) to account for the multiple time
points at which measurements were taken at altitude and the different
ascent profiles of each trek group. All p values report the treatment
effect in response to taking the high nitrate dietary supplement unless
otherwise specified separately in the text. All reported variables were
either normally distributed, or converted into normally distributed data
after logarithmic transformation (where transformation was performed
this is specified in Table 2). Significance was assumed when p < 0.05,
and a sensitivity analysis was performed with any missing values re-
placed by mean values to verify the model. Where variables were not
normally distributed before transformation, descriptive values are re-
ported as median (interquartile range) as appropriate to keep values in
the original units for ease of understanding of the reader. Values for all
variables that were normally distributed are reported as mean
(± standard deviation).
3. Results
As reported previously, 1 participant was evacuated soon after ar-
riving at 4559m for medical reasons and did not complete any testing
at altitude [30]. All other participants were able to undergo testing at
altitude and all experimental protocols were conducted successfully.
3.1. Hemoglobin and plasma markers
Mean hemoglobin concentration slightly increased with altitude
exposure in both groups, and this effect was not influenced by the ni-
trate intervention (see Table 1).
Dietary nitrate supplementation increased plasma nitrate con-
centrations 4-fold compared to the placebo group, both at sea level and
at altitude (p < 0.001). Nitrate supplementation also significantly in-
creased both plasma nitrite (p= 0.03) and total nitroso product
(p < 0.001) concentrations, both at sea level and at altitude. However,
fasting plasma nitrite concentrations were more than 50% lower at
4559m compared to sea level in both the treatment and the placebo
groups (see Tables 1 and 2).
As expected, cGMP concentrations also decreased on arrival at al-
titude in both groups, but there was no significant difference in cGMP
levels with high nitrate treatment (see Tables 1 and 2). Similarly,
dietary nitrate supplementation did not significantly alter plasma L-ar-
ginine or plasma protein concentrations either (p= 0.73 and 0.90 re-
spectively), but mean plasma arginase activity was significantly higher
(p= 0.04) in the high nitrate treatment group (see Tables 1 and 2).
3.2. Sublingual blood vessel density and blood flow
The Total Vessel Density (TVD), Proportion of Perfused Vessels
(PPV) and Microcirculatory Flow Index (MFI) for all measured vessels,
and specifically for the smallest measured blood vessels (defined as
those < 25 μm in diameter), both at sea level and at altitude, are
Table 1
Descriptive table for sea level (SL) and respective testing days at altitude.
Haemoglobin samples were taking during the first 3 days at 4559m, plasma
samples were taken on 1st (D1), 3rd (D3) and 5th (D5) testing days at 4559m.
Data are presented as median (IQR) or mean (± SD) as appropriate. RxNO –
total nitroso products; cGMP – cyclic guanosine monophosphate.
Placebo Treatment
Haemoglobin
(g/dL)
SL 15.0 (± 1.1) 15.0 (±0.9)
MH 16.1 (± 1.4) 15.8 (±1.0)
Plasma Nitrate
(μM)
SL 19.2 (16.0–22.3) 76.9 (68.3–110.6)
D1 20.9 (17.3–22.8) 85.7 (70.5–102.0)
D3 19.9 (16.9–22.9) 83.0 (74.2–95.2)
D5 22.9 (22.0–26.4) 84.3 (66.9–101.0)
Plasma Nitrite
(μM)
SL 0.779
(0.682–0.863)
0.856 (0.623–1.594)
D1 0.332
(0.205–0.387)
0.355 (0.303–0.451)
D3 0.311
(0.228–0.387)
0.378 (0.301–0.448)
D5 0.312
(0.270–0.343)
0.409 (0.354–0.447)
Plasma RxNO
(nM)
SL 11.3 (8.6–13.6) 19.7 (12.5–29.1)
D1 10.8 (9.6–11.5) 15.0 (12.8–15.9)
D3 10.6 (7.9–12.7) 11.9 (11.3–17.5)
D5 9.7 (9.1–11.0) 12.3 (11.7–16.6)
Plasma cGMP
(nM)
SL 234.8 (± 70.8) 207.5 (± 67.4)
D1 144.6 (± 45.4) 174.4 (± 73.7)
D3 161.2 (± 54.6) 192.0 (± 99.1)
D5 203.0 (± 78.1) 164.3 (± 61.3)
Plasma L-Arginine
(μg/ml)
SL 6.3 (4.7 - 8.7) 8.4 (2.6 - 14.8)
D3 7.5 (5.7 - 16.9) 9.4 (5.8 - 33.0)
D5 8.9 (4.5 - 15.7) 7.4 (6.1–36.7)
Plasma Arginase activity
(Units/L)
SL 12.8 (± 3.5) 14.9 (±3.6)
D3 12.4 (± 2.4) 12.5 (±2.7)
D5 12.1 (± 1.7) 12.7 (±2.4)
Plasma Protein
concentration
(g/L)
SL 79.5 (± 15.4) 91.6 (±15.3)
D1 89.4 (± 30.1) 92.4 (±20.2)
D3 84.4 (± 24.4) 85.6 (±28.6)
D5 79.8 (± 23.5) 77.2 (±23.2)
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shown in Fig. 2. Corresponding regression and significance data is de-
tailed in Table 3.
Despite the significant biochemical increases seen in response to
high nitrate dietary supplementation described above, no significant
differences were seen in any measure of sublingual microcirculatory
function in response to treatment with high nitrate supplementation.
3.3. Forearm blood flow measurements
The handgrip protocol successfully resulted in measureable in-
creases in forearm blood flow after a standardised exercise protocol,
both at sea level and at altitude. At sea level, large increases in blood
Table 2
Regression coefficients for each plasma biomarker showing: regression coeffi-
cient, 95% confidence interval (95% CI) and p-values for the effect the treat-
ment (dietary nitrate supplementation) had on each measured variable. The
treatment (dietary nitrate supplementation) group displayed significant higher
levels of plasma nitrate, nitrite, RxNO and arginase activity.
Variable Regression coefficient (95% CI) p-value
Haemoglobin 0.02 (−0.77, 0.82) 0.95
Log Plasma Nitrate 1.5 (1.3, 1.7) < 0.001
Log Plasma Nitrite 0.3 (0.04, 0.6) 0.03
Log Plasma RxNO 0.5 (0.2, 0.8) < 0.001
Plasma cGMP −1.2 (−28.0, 25.6) 0.93
Log Plasma L-Arginine 0.11 (−0.51, 0.72) 0.73
Plasma Arginase 2.1 (0.11, 40) 0.04
Plasma Protein 0.77 (−10.7, 12.2) 0.90
Fig. 2. Comparison of microcirculatory function at sea level and high altitude. A=Total Vessel Density (TVD) for vessels that are < 25 μm diameter or all vessels, at
sea level and at 4559m altitude. B = Proportion of Perfused Vessels (PPV) for vessels that are < 25 μm diameter or all vessels, at sea level and at 4559m altitude.
C=Microcirculatory Flow Index (MFI) for vessels that are < 25 μm diameter or all vessels, both at sea level at 4559m altitude. Open points represent the placebo
(low nitrate dietary supplement) group; solid boxes represent the treatment (high nitrate dietary supplement) group. Circular points represent vessels< 25 μm in
diameter, square points represent all vessels.
Table 3
Regression coefficients for sublingual microcirculatory data measured with
sidestream dark field (SDF) imaging; regression coefficient, 95% confidence
interval (95% CI) and p values for the effect of treatment with high nitrate
dietary supplementation on Total Vessel Density (TVD), Proportion of Perfused
Vessels (PPV) and Microcirculatory Flow Index (MFI) are given below. There
was no significant change seen in any measurement of sublingual micro-
circulatory flow in response to treatment with high nitrate dietary supple-
mentation.
Variable (vessel size) Regression coefficient (95% CI) p-value
TVD (Small) 0.55 (−1.9, 3.0) 0.66
TVD (All) 1.12 (−0.37, 2.62) 0.14
PPV (Small) −7.23 (−19.1, 5.3) 0.26
PPV (All) −6.25 (−18.3, 5.8) 0.31
MFI (Small) −0.05 (−0.3, 0.2) 0.7
MFI (All) −0.02 (−.02, 0.2) 0.8
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flow were observed; from 3.3 (± 1.5) %/min to 19.9 (± 7.0) %/min in
the placebo group and from 3.3 (± 1.8) %/min to 19.1 (± 8.0) %/min
in the treatment group. Similar changes were also seen at 4559m, al-
though both the placebo and the treatment groups displayed more
moderate increases in peak forearm blood flow with exercise at altitude
(see Fig. 3).
As with all reported measures of sublingual microcirculatory func-
tion above, the increase in forearm microcirculatory blood flow with
exercise did not change with dietary nitrate supplementation in any
measureable way, neither at sea level nor at altitude. Similarly, when
environmental conditions were experimentally reversed by breathing
12% oxygen for 45min at sea level or by inhaling 35% for 45min at
4559m altitude, there was still no significant difference in forearm
blood flow between the placebo and treatment groups (see Fig. 3).
Furthermore, the regression data from our statistical model revealed
that the dietary nitrate intervention had no significant effect on forearm
blood flow under any of the experimental conditions tested (data not
shown).
4. Discussion
Our findings show that dietary nitrate supplementation significantly
increases circulating levels of nitrate, nitrite and nitroso product con-
centrations, both at sea level and at 4559m altitude. However, despite
these significant biochemical changes, there was no demonstrable im-
provement in any measure of sublingual microcirculatory function or
forearm blood flow (either at rest or after handgrip exercise, and under
normal or reversed environmental conditions), suggesting that overall
NO bioavailability remained unaltered both at sea level and at altitude.
In a number of previous studies, dietary nitrate supplementation has
been demonstrated to increase plasma nitrite (and/or nitrate) con-
centrations and result in improved running performance, walking per-
formance, and cycling performance under conditions of normobaric
hypoxia [37–40]. However, almost all of these studies investigated the
effect of dietary supplementation on the function of relatively large
muscle groups or even whole body performance. Few studies have in-
vestigated the effects of nitrate supplementation on the microcircula-
tion, even though microcirculatory adaptations may be crucial to how
Sherpas can perform so well under extreme hypoxia [18].
A similar study to ours has recently also reported no significant
change to forearm blood flow during acute exposure to a simulated
altitude of 4300m, despite increasing plasma nitrate levels 10-fold
[41]. Interestingly, the single dose of 15mmol nitrate used in that trial
did not change peripheral oxygen saturations (SpO2) either despite
increasing exhaled NO levels (PENO) by 24%, also supporting previous
findings of the Xtreme Alps study [30]. However, unlike the Xtreme
Alps study, that trial used a single dose of nitrate and a relatively short
period of simulated hypobaric hypoxia, which is likely to be a very
different physiological stimulus to chronic field exposure to hypobaric
hypoxia as in the Xtreme Alps study [42]. In another chamber study,
approximately 6.4mmol nitrate daily for 5 days (a very similar dose to
our intervention) increased plasma nitrate levels by over 180 μM, yet
this exacerbated AMS symptoms, worsened sense of effort and in-
creased blood pressure during walking exercise in participants suscep-
tible to AMS exposed to up to 6 h of acute hypoxia [43]. Meanwhile, in
other field studies exposing subjects to hypobaric hypoxia, daily sup-
plementation with approximately 10mmoles nitrate demonstrated no
improvement in sleep disordered breathing in lowlanders at altitudes
between 3700m and 4900m in the Himalayas over 2 consecutive days
[44], nor any improvement in adolescents’ AMS scores over 7 days at
altitudes up to 5300m [45].
Decreases in microcirculatory blood flow at higher altitudes in na-
tive lowlanders, similar to the findings reported here, have been well
documented previously [16,17,24]. The findings demonstrated here do
support these results again even though treatment with nitrate had no
effect and all decreases seen were small – possibly due to the shorter
duration of altitude exposure in this study compared to previous studies
in the Himalaya [16,17,24]. Notably though, reduced microcirculatory
blood flow was previously found to be associated with higher plasma
nitrite concentrations [24]. The fact that in the Xtreme Alps study,
plasma nitrite concentrations decreased at altitude compared to sea
level - despite dietary nitrate supplementation - is a curious finding and
may explain the lack of physiological acclimatisation responses seen in
this cohort.
We cannot exclude that an even higher nitrate dose might have
affected microvascular function. We are aware that more recent studies
have used higher doses of nitrate and also investigated the dose-re-
sponse curve of nitrate [46]; however none of these findings were
available when our study was originally designed (2008/09). We have
demonstrated previously that the dietary nitrate contained in this
beetroot supplement was subject to enterosalivary circulation with
consecutive reduction of nitrate to nitrite in the oral cavity, resulting in
highly significant increases in nitrite levels in saliva and significant
increases of NO in exhaled breath as well as exhaled breath condensate
[30]. Why this increased availability in oral nitrite did not also translate
into increased concentrations of nitrite in blood plasma remains
Fig. 3. Forearm blood flow data from sea level and altitude. Each graph shows the increase in the initial forearm circumference caused by the inflow of arterial blood
into newly opened microcirculatory vessels before (Baseline - BL) and after (Handgrip - HG) 2min of standardised exercise both at Sea Level and at 4559m Altitude.
Overlying error bars represent the mean ± SD.
Subjects taking the placebo (P) and treatment (T) supplements are represented by open and solid data points, respectively.
Graph A=normal environmental conditions; i.e. normoxia at sea level represented by circular points, and hypoxia at altitude represented by squares.
Graph B= reverse environmental conditions; i.e. after breathing 12% oxygen for 45min at sea level (to mimic acute altitude exposure) represented by hexagonal
data points, and breathing 35% oxygen for 45min at 4559m (to mimic being in London) represented by diamonds.
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unclear.
One possible explanation might be that the pharmacological effects
of nitrate are critically dependent on the dosing regimen and thus not
simply a function of the total dose administered and steady state-con-
centrations achieved. Unlike in other previous studies, the nitrate
supplementation in our Xtreme Alps study was administered in three
equally divided doses throughout the day with the aim of maintaining
more consistent elevations in plasma concentrations of nitrate and re-
lated metabolic products [30]. This may have translated into lower
peak concentrations of nitrite, nitroso and nitrosyl products and inter-
connected elements of the Reactive Species Interactome, consequently
reducing the magnitude of the system's response [47]. In support of this
suggestion, other studies administering high dose nitrate in divided
portions over a more sustained period of time (4 week intervals) have
also failed to demonstrate measurable decreases in blood pressure
normally seen in response to an acute nitrate administration [48]. Al-
ternatively, as the authors of this particular study discuss, the effects of
sustained increases in plasma nitrate may chronically alter enzyme
expression, and prolonged exposure to other dietary factors (such as
sulfate) may further modify nitrate's effects [49,50]. Moreover, there
now appears to be less evidence to support the original concept of
hypoxia-dependent nitrite/NO-mediated increases in blood flow fol-
lowing nitrate supplementation. Indeed, most recent investigations in
mice have demonstrated that bolus administration of nitrite induces
microvascular dilatation in an NO-independent manner, with blood
pressure changes secondary to redox-induced dimerization of protein
kinase G1α, independent of either NO or cGMP [51]. This effect may
also underlie the concerted cardio-protective response to brief eleva-
tions in plasma nitrite described previously, which were associated with
a number of redox, metabolic and cardiac signalling changes [52].
Whether these results are translatable to humans remains to be in-
vestigated.
Our observations might also suggest that nitrite utilisation is en-
hanced in hypobaric hypoxia and/or that nitrite is being sequestered in
other body compartments that have not been measured here. Equally
little is known currently about the elimination and renal handling of
nitrite and nitrate, although a recent study suggested that either one or
both of these species may have direct effects on the renal tubular bed
[53]. Given that altitude exposure alone (without any supplementation)
affects renal function [54], the combined effect of taking nitrate sup-
plementation at altitude on renal function warrants further investiga-
tion. Similarly, so does the effect beetroot-based juices have on nitrite
levels in other body compartments, as well as on whole body exercise
performance. Circulating concentrations of nitrite and nitrate in blood
will ultimately be determined by the balance of dietary intake; en-
dogenous NO production and its conversion to nitrate, enterosalivary
circulation and microbial reduction to nitrite; as well as the excretion
and uptake (but possibly also the release) of nitrite and nitrate by tis-
sues. Relatively little is known about these processes in humans.
4.1. Strengths and limitations
To our knowledge, the Xtreme Alps study remains one of the largest
studies to date investigating the effects of dietary nitrate supple-
mentation under hypobaric hypoxia performed under field conditions
at high altitude. Using intervention and placebo supplements (identical
both in appearance and taste) allowed the study to use a double-blinded
design and added reliability despite the many challenges that per-
forming a study of this nature carries. Space on the mountain limited
overall sample sizes and therefore the power of the study; potentially
both increasing the risk of type 2 errors, and also reducing the positive
predictive value of statistically significant results (the so-called ‘win-
ner's curse’) [55]. We attempted to overcome this by taking two sepa-
rate trek groups and planning identical (staggered) ascent profiles to
allow direct comparison, however an incoming storm forced one trek to
ascend to 4559m one day earlier than the other. This has been
accounted for, as much as possible, in the statistical model used for data
analysis, and trends were still similar across both trekking groups. As
each subject started their intervention juice drink three days before
each testing period (both at sea level and at altitude) we were unable to
measure untreated baseline values, and equally we could not include a
full ‘intervention-free’ control group without further compromising the
size of each intervention group. However, the few measurements that
were taken on untreated members of laboratory staff all closely mat-
ched values of the placebo group, as we have reported previously [30].
Even though our cohort was predominately comprised of young males
with some previous altitude experience this is actually a representative
sample of the population who visit high altitude regions considering
that most patients seen at the Everest Base Camp clinic over the last ten
years have been males below 40 years of age [56].
5. Conclusions
Dietary nitrate supplementation at altitude can significantly in-
crease levels of circulating nitrate and other NO-related metabolites.
However, despite these marked biochemical changes, we did not
identify any significant alteration to sublingual or forearm micro-
circulatory flow whilst living at 4559m for over five days. This is
consistent with the lack of effects on blood pressure, respiratory func-
tion and peripheral oxygen saturation reported by us previously in re-
sponse to treatment with dietary nitrate supplementation [30]. How-
ever, this lack of improvement to small vessel function at altitude does
not necessarily mean that dietary nitrate supplementation will have no
effect on other organ systems or confers no benefit on overall exercise
performance at altitude, and both of these areas merit further in-
vestigation.
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